1h Free Analyst Time
Oxurion NV (OXUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.Speak directly to the analyst to clarify any post sales queries you may have.
The profile contains critical company information including:
- Business description - A detailed description of the company's operations and business divisions.
- Corporate strategy - Analyst's summarization of the company's business strategy.
- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Oxurion NV (Oxurion), formerly ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer therapeutics. The company's ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). Oxurion's product pipeline includes THR-687, a pan-RGD integrin antagonist being developed for the treatment of diabetic retinopathy, and THR-149, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema (DME). It has commercialization agreements with companies such as BioInvent International, Quintiles Outcome Sciences, Bicycle Therapeutics, Galapagos, Parexel, INC Research, Grifols Inc, Patheon, and Alcon. It has a presence in Belgium, Ireland and the US. Oxurion is headquartered in Leuven, Flemish Brabant, Belgium.Oxurion NV Key Recent Developments
- Sep 07, 2022: Oxurion Publishes First Half 2022 Results
- Jun 13, 2022: Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting
- Jun 01, 2022: Oxurion to Participate in Upcoming Investor Conferences
- May 24, 2022: Oxurion Announces Results of the Extraordinary Shareholders' Meeting held on 24 May 2022
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Samples
LOADING...
Companies Mentioned
A selection of companies mentioned in this report includes:
- Rocket Pharmaceuticals Inc
- Oncotelic Therapeutics Inc
- Amakem NV
- Phio Pharmaceuticals Corp
- IVERIC bio Inc
- Kubota Vision Inc